Articles from RevolKa Ltd.

RevolKa Ltd. (RevolKa), a venture-backed biotech company providing an advanced AI protein engineering technology platform, called aiProtein®, is pleased to announce the official global launch of RevoAb®, an innovative and quick online service for antibody sequence optimization to solve challenges in physicochemical properties, especially antibody yields.

RevolKa Ltd. (RevolKa), a venture-backed biotech company providing a cutting-edge AI-driven protein engineering technology platform, called aiProtein® is pleased to announce the launch of a new contract research service, 'RevoAb™'. This service engineers antibodies to improve physicochemical properties while protecting antigen binding affinity.

RevolKa Ltd. (RevolKa), a venture-backed biotech company providing a cutting-edge AI-driven protein engineering technology platform, called aiProtein® has announced its participation in a research and development program funded by a government grant of 54 million JPY (approximately US$372K for the first year) from the Japanese Agency for Medical Research and Development (AMED). This project, set to continue over 4 years, is led by Prof. Mitsuo Umetsu of Tohoku University, who also serves as RevolKa’s Chief Scientific Officer. This opportunity will further accelerate RevolKa’s rare disease drug discovery and development efforts, previously announced on July 30th, 2024. (https://www.revolka.com/news/english/collab-en/a65). RevolKa’s core technology, aiProtein®: a robust directed protein evolution platform integrated with AI (artificial intelligence) creates exceptionally high performance proteins, going beyond natural evolution and offering advantages for therapeutic strategies. aiProtein® has generated many successful outcomes with many partner companies.

RevolKa Ltd. (RevolKa), a venture-backed biotech company providing a cutting-edge AI-driven protein engineering technology platform called aiProtein®, has raised 210 million JPY (US$1.4M) in Series A extension funding. This funding will advance RevolKa’s drug discovery programs for rare diseases (https://www.revolka.com/news/english/collab-en/a65) and support collaborative partnering efforts. This financing round was co-led by existing investors, D3 LLC (Tomoya Nagata, Managing Partner, CEO) and TOHOKU University Venture Partners Co., Ltd. (Tetsuro Higuchi, President & CEO) with participation from DEEPCORE Inc. (Katsumasa Niki, President & CEO). RevolKa’s core technology, aiProtein® is a robust AI-driven protein engineering technology that creates exceptionally high-performance proteins. This technology platform has already produced many successful outcomes in collaboration with partner companies.

RevolKa Ltd. (RevolKa), a venture-backed biotech company providing a cutting-edge AI-driven protein engineering technology platform, called aiProtein® announced the closing of a 100 million JPY (US$0.7M) financing, and has completed a total of 250 million JPY (US$1.7M) in the Series A extension funding. We also announced the launch of a drug discovery program for rare diseases on July 30th, 2024. (https://www.revolka.com/news/english/collab-en/a65) Some of our drug candidates in this program have achieved positive in vitro proof-of-concept. D3 LLC (Tomoya Nagata, Managing Partner, CEO) co-led the Series A extension round along with DEEPCORE Inc. (Katsumasa Niki, President & CEO). The funds will accelerate RevolKa’s drug discovery and development activities. Our core technology, aiProtein®: a robust directed protein evolution technology integrated with AI (artificial intelligence) creates incredibly high performance proteins, going beyond natural evolution. This technology generated many successful stories in collaboration with partner companies.

RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform (Norio Hamamatsu, President and CEO) signed a master service agreement with Daiichi Sankyo Co., Ltd. (Hiroyuki Okuzawa, President and COO). RevolKa will create and deliver highly functional proteins, in collaboration with Daiichi Sankyo Co., Ltd. by using its proprietary protein engineering platform technology, called aiProtein®: a robust directed protein evolution technology integrated with artificial intelligence (AI). Details of this agreement and financial terms were not disclosed.

RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a research collaboration to create antigens for the next-generation vaccines to deliver innovative solutions to unmet medical need in infectious diseases. RevolKa has a robust directed protein evolution technology integrated with artificial intelligence (AI), called aiProtein®. LJI and RevolKa will synergize LJI’s deep knowledge of immunology and RevolKa’s power of AI-driven protein engineering. Details of this collaboration and financial terms were not disclosed.

RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform (Shiro Kataoka, CEO) signed a contract research agreement with SEKISUI CHEMICAL CO., LTD. (Keita Kato, President & Representative Director). RevolKa will create and deliver highly functional proteins by using its proprietary protein engineering platform technology, called aiProtein®: a robust directed protein evolution technology integrated with artificial intelligence (AI). Details of this agreement and financial terms were not disclosed.

RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform (Shiro Kataoka, CEO) is pleased to announce the successful completion of the collaborative drug discovery project with Sumitomo Pharma Co., Ltd. (Hiroshi Nomura, President and CEO) for rare diseases within the contractually agreed time frame. RevolKa designed and identified lead candidates by using its proprietary technology platform called aiProtein®: a robust directed protein evolution technology integrated with artificial intelligence (AI). These lead candidates remarkably exceeded the criteria set in the project. RevolKa delivered them for Sumitomo Pharma’s further research and development for pharmaceutical drug applications. Based on the result, Sumitomo Pharma and RevolKa agreed to declare the milestone achievement. Sumitomo Pharma will receive a right of first refusal to an exclusive license of the molecules. RevolKa was entitled to milestone payment. Specific financial terms were not disclosed.